midazolam d4 (LGC Standards)
LGC Standards is a verified supplier 
LGC Standards manufactures this product 
95
Structured Review
LGC Standards
midazolam d4
Midazolam D4, supplied by LGC Standards, used in various techniques. Bioz Stars score: 95/100, based on 167 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/midazolam+d4/Pregabalin/pm41607161-50-7-24
Average 95 stars, based on 167 article reviews
Midazolam D4, supplied by LGC Standards, used in various techniques. Bioz Stars score: 95/100, based on 167 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/midazolam+d4/Pregabalin/pm41607161-50-7-24
Average 95 stars, based on 167 article reviews
midazolam d4 - by Bioz Stars,
2026-09
95/100 stars
Images
Related Articles
Clinical Proteomics:Article Title: In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients. Article Snippet: Cyclosporine and tacrolimus, two calcineurin inhibitors, are characterized by highly variable pharmacokinetics and a narrow therapeutic window.1 Despite these unfavorable characteristics, these drugs have become cornerstones of immunosuppressive therapy in solid-organ transplantation.2,3 Although tacrolimus has gradually replaced cyclosporine in immunosuppressive regimens in de novo allograft recipients, a substantial number of patients are still maintained on cyclosporine therapy.2,3 In addition, both cyclosporine and tacrolimus are widely used in the treatment of several immunemediated diseases.. Despite major differences in molecular structure, these two calcineurin inhibitors share the same pathways for absorption, distribution, metabolism, and excretion.4,5 The oral bioavailability and systemic clearance of these drugs are controlled mainly by the cytochrome P450 isoenzymes CYP3A4 and 3A5 and the drug transporter P-glycoprotein, which are expressed in enterocytes (affecting oral bioavailability) and hepatocytes (affecting both oral bioavailability and systemic clearance).5,6 This implies that each of the drugs is prone to drug–drug interactions caused by concomitant administration of CYP3A and/or P-glycoprotein inducers/inhibitors.4,7 Importantly, in vitro studies have shown that both cyclosporine and tacrolimus are not only substrates of CYP3A isoenzymes but also inhibit these enzymes.8 Hence, both drugs have the potential to cause CYP3A-mediated drug–drug interactions in vivo.8,9 This is of major clinical importance because many patients who are treated with calcineurin inhibitors also receive other drugs that are CYP3A substrates, for example, corticosteroids and various drugs used for treating associated conditions such as arterial hypertension, hyperlipidemia, and infections.. However, it is very difficult to directly extrapolate these in vitro data to a real-life clinical setting. Chromatography:Article Title: In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients. Article Snippet: Cyclosporine and tacrolimus, two calcineurin inhibitors, are characterized by highly variable pharmacokinetics and a narrow therapeutic window.1 Despite these unfavorable characteristics, these drugs have become cornerstones of immunosuppressive therapy in solid-organ transplantation.2,3 Although tacrolimus has gradually replaced cyclosporine in immunosuppressive regimens in de novo allograft recipients, a substantial number of patients are still maintained on cyclosporine therapy.2,3 In addition, both cyclosporine and tacrolimus are widely used in the treatment of several immunemediated diseases.. Despite major differences in molecular structure, these two calcineurin inhibitors share the same pathways for absorption, distribution, metabolism, and excretion.4,5 The oral bioavailability and systemic clearance of these drugs are controlled mainly by the cytochrome P450 isoenzymes CYP3A4 and 3A5 and the drug transporter P-glycoprotein, which are expressed in enterocytes (affecting oral bioavailability) and hepatocytes (affecting both oral bioavailability and systemic clearance).5,6 This implies that each of the drugs is prone to drug–drug interactions caused by concomitant administration of CYP3A and/or P-glycoprotein inducers/inhibitors.4,7 Importantly, in vitro studies have shown that both cyclosporine and tacrolimus are not only substrates of CYP3A isoenzymes but also inhibit these enzymes.8 Hence, both drugs have the potential to cause CYP3A-mediated drug–drug interactions in vivo.8,9 This is of major clinical importance because many patients who are treated with calcineurin inhibitors also receive other drugs that are CYP3A substrates, for example, corticosteroids and various drugs used for treating associated conditions such as arterial hypertension, hyperlipidemia, and infections.. However, it is very difficult to directly extrapolate these in vitro data to a real-life clinical setting. Concentration Assay:Article Title: Pharmacokinetics of midazolam, 1´-OH-midazolam, 4-OH-midazolam, 1´-OH-midazolam-β-D-glucuronide, and 4-OH-midazolam-β-D-glucuronide in serum and urine from patients undergoing cardiac surgery. Article Snippet: Background: The benzodiazepine midazolam is widely used preand intraoperatively in intensive care units.. 1 ́-OH-midazolam, one of the major metabolites, is pharmacologically active.. Accumulation of 1 ́-OH-midazolam, e.g. due to hepatic dysfunction or renal insufficiency, may therefore enhance pharmacological activity. |